MX367908B - Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina. - Google Patents

Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina.

Info

Publication number
MX367908B
MX367908B MX2017001930A MX2017001930A MX367908B MX 367908 B MX367908 B MX 367908B MX 2017001930 A MX2017001930 A MX 2017001930A MX 2017001930 A MX2017001930 A MX 2017001930A MX 367908 B MX367908 B MX 367908B
Authority
MX
Mexico
Prior art keywords
prepare
tetrahydroquinoline derivatives
derivatives
preparation
level
Prior art date
Application number
MX2017001930A
Other languages
English (en)
Spanish (es)
Other versions
MX2017001930A (es
Inventor
Ford John
Paulus Gerardus Seerden Johannes
Ledru Amandine
Original Assignee
Dezima Pharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51429345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367908(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dezima Pharma B V filed Critical Dezima Pharma B V
Publication of MX2017001930A publication Critical patent/MX2017001930A/es
Publication of MX367908B publication Critical patent/MX367908B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2017001930A 2014-08-12 2015-07-29 Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina. MX367908B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2014050556 2014-08-12
PCT/NL2015/050555 WO2016024858A1 (en) 2014-08-12 2015-07-29 Process for preparing synthetic intermediates for preparing tetrahydroquinoline derivatives

Publications (2)

Publication Number Publication Date
MX2017001930A MX2017001930A (es) 2018-03-01
MX367908B true MX367908B (es) 2019-09-11

Family

ID=51429345

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001930A MX367908B (es) 2014-08-12 2015-07-29 Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina.

Country Status (28)

Country Link
US (1) US10112904B2 (https=)
EP (2) EP3180314B1 (https=)
JP (1) JP6670310B2 (https=)
KR (1) KR102572626B1 (https=)
CN (1) CN107108558B (https=)
AR (1) AR101509A1 (https=)
AU (1) AU2015302407B2 (https=)
BR (1) BR112017002873B1 (https=)
CA (1) CA2958040C (https=)
CL (1) CL2017000367A1 (https=)
CY (1) CY1125574T1 (https=)
DK (1) DK3180314T3 (https=)
EA (1) EA034357B1 (https=)
ES (1) ES2926775T3 (https=)
HR (1) HRP20221061T1 (https=)
HU (1) HUE059947T2 (https=)
IL (1) IL250525B (https=)
LT (1) LT3180314T (https=)
MA (1) MA40378B1 (https=)
MX (1) MX367908B (https=)
PL (1) PL3180314T3 (https=)
PT (1) PT3180314T (https=)
RS (1) RS63575B1 (https=)
SG (1) SG11201701077XA (https=)
SI (1) SI3180314T1 (https=)
SM (1) SMT202200385T1 (https=)
TW (1) TWI691490B (https=)
WO (1) WO2016024858A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4125911B1 (en) 2021-03-05 2024-04-24 NewAmsterdam Pharma B.V. Obicetrapib for treatment of dementias
IL310115A (en) 2021-07-26 2024-03-01 Newamsterdam Pharma B V Treatment of his hyporesponders
AU2022425078A1 (en) 2021-12-30 2024-08-08 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
CU20250001A7 (es) 2022-07-05 2025-10-17 Newamsterdam Pharma B V Sales de obicetrapib y procesos para su fabricación y productos intermedios de estos
TW202416994A (zh) 2022-08-22 2024-05-01 荷蘭商新阿姆斯特丹製藥公司 固定劑量醫藥組合物及其用途
EP4661865A1 (en) 2023-02-07 2025-12-17 NewAmsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025059594A1 (en) 2023-09-15 2025-03-20 Newamsterdam Pharma B.V. METHODS FOR TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025093436A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor
WO2025146262A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies
WO2025146415A1 (en) 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Improvement in atherosclerotic plaque characteristics with obicetrapib
WO2026062050A1 (en) 2024-09-17 2026-03-26 Newamsterdam Pharma B.V. Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd)
WO2026062049A1 (en) 2024-09-21 2026-03-26 Newamsterdam Pharma B.V., Obicetrapib for the treatment of dementias
WO2026063944A1 (en) 2024-09-21 2026-03-26 Newamsterdam Pharma B.V. Obicetrapib for the treatment of dementias

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
ATE316957T1 (de) * 2001-04-30 2006-02-15 Pfizer Prod Inc Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
CN101466679A (zh) * 2006-03-30 2009-06-24 田边三菱制药株式会社 制备四氢喹啉衍生物的方法
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
JP6670310B2 (ja) 2020-03-18
PT3180314T (pt) 2022-09-02
EP4083022A1 (en) 2022-11-02
EP3180314A1 (en) 2017-06-21
IL250525A0 (en) 2017-03-30
CA2958040A1 (en) 2016-02-18
MX2017001930A (es) 2018-03-01
HRP20221061T1 (hr) 2022-11-25
CN107108558B (zh) 2019-11-19
CN107108558A (zh) 2017-08-29
EA201790364A1 (ru) 2017-07-31
DK3180314T3 (da) 2022-08-29
HUE059947T2 (hu) 2023-01-28
IL250525B (en) 2019-08-29
SI3180314T1 (sl) 2022-11-30
JP2017524742A (ja) 2017-08-31
AU2015302407A1 (en) 2017-03-02
AR101509A1 (es) 2016-12-21
TW201613868A (en) 2016-04-16
CY1125574T1 (el) 2026-02-25
SG11201701077XA (en) 2017-03-30
MA40378A (fr) 2017-06-21
WO2016024858A1 (en) 2016-02-18
MA40378B1 (fr) 2022-10-31
CL2017000367A1 (es) 2018-02-09
BR112017002873A2 (pt) 2018-07-17
LT3180314T (lt) 2022-11-10
CA2958040C (en) 2022-09-13
KR20170102204A (ko) 2017-09-08
US20170267640A1 (en) 2017-09-21
BR112017002873B1 (pt) 2023-03-28
KR102572626B1 (ko) 2023-08-30
PL3180314T3 (pl) 2022-11-21
RS63575B1 (sr) 2022-10-31
AU2015302407B2 (en) 2019-09-19
BR112017002873A8 (pt) 2022-11-08
ES2926775T3 (es) 2022-10-28
TWI691490B (zh) 2020-04-21
SMT202200385T1 (it) 2022-11-18
US10112904B2 (en) 2018-10-30
EA034357B1 (ru) 2020-01-30
EP3180314B1 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
MX367908B (es) Proceso para preparar intermediarios sinteticos para preparar derivados de tetrahidroquinolina.
EA201691582A1 (ru) Новые фармацевтические препараты
EA201790806A1 (ru) Иммунорегулирующие средства
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
EA201790998A1 (ru) Иммуннорегуляторные агенты
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
EP3122782A4 (en) Compositions and methods for treatment of diabetic macular edema
SG10201806846RA (en) Cyclopropylamines as lsd1 inhibitors
EP3151818A4 (en) Compositions and methods of treating diabetic retinopathy
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
EP3096617A4 (en) Compositions and methods for treating ocular diseases
EP3240612A4 (en) Methods of treating retinal diseases
HUE059303T2 (hu) Acetilkolin-észteráz-gátlók bõrbetegségek kezelésére
EP3157531A4 (en) Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
IL247116B (en) Compositions and methods for treating and preventing macular degeneration
ZA201703467B (en) Methods of treating ocular conditions
EP3386507A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF STOMACH DISEASES
EP3322406A4 (en) TRANSPAPILLARY METHOD AND COMPOSITION FOR THE TREATMENT OF BREAST DISEASES
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
EP3145532A4 (en) Individualized treatment of eye disease
EP3129361A4 (en) Treatment of neurodegenerative diseases with asparagine endopeptidase (aep) inhibitors and compositions related thereto
EP3156054A4 (en) Medicine for preventing and/or treating stress-induced diseases
EP3261652A4 (en) Extract of taiwanese propolis for treating ocular diseases
EP3294417A4 (en) COMPOSITIONS AND METHOD FOR TREATING GLIOM
EP3230254A4 (en) Compositions and methods for treating diseases and conditions

Legal Events

Date Code Title Description
FG Grant or registration